This was not predictable considering some studies that showed a 15-year actuarial risk of contralateral breast cancer of 36.1% for women with P/LP variants BRCA1 and 28.5% for women with P/LP variants in BRCA2 (Metcalfe et al. 2011). This evidence concerns the gene BRCA2 and breast cancer.